Cantor Fitzgerald set a $9.00 target price on Applied Genetic Technologies Corporation (NASDAQ:AGTC) in a research note released on Friday. The firm currently has a hold rating on the biotechnology company’s stock.

“Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy.”,” Cantor Fitzgerald’s analyst commented.

Several other research firms have also commented on AGTC. ValuEngine lowered Applied Genetic Technologies Corporation from a hold rating to a sell rating in a report on Friday, September 15th. HC Wainwright reaffirmed a buy rating and set a $8.00 target price (down from $16.00) on shares of Applied Genetic Technologies Corporation in a report on Thursday, September 14th. BMO Capital Markets reaffirmed an outperform rating and set a $7.00 target price (down from $14.00) on shares of Applied Genetic Technologies Corporation in a report on Thursday, September 14th. Stifel Nicolaus lowered their target price on Applied Genetic Technologies Corporation from $15.00 to $12.00 and set a buy rating for the company in a report on Thursday, September 14th. Finally, Zacks Investment Research raised Applied Genetic Technologies Corporation from a sell rating to a hold rating in a report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $11.71.

Applied Genetic Technologies Corporation (NASDAQ AGTC) opened at 4.05 on Friday. Applied Genetic Technologies Corporation has a 1-year low of $3.50 and a 1-year high of $10.85. The stock has a market cap of $73.25 million, a P/E ratio of 202.50 and a beta of 1.63. The company’s 50-day moving average price is $4.20 and its 200-day moving average price is $5.13.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last announced its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.40). The firm had revenue of $8.30 million during the quarter, compared to the consensus estimate of $12.39 million. Applied Genetic Technologies Corporation had a net margin of 4.28% and a return on equity of 1.45%. The firm’s quarterly revenue was down 31.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.15 earnings per share. Analysts predict that Applied Genetic Technologies Corporation will post ($0.81) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Applied Genetic Technologies Corporation (AGTC) Given a $9.00 Price Target at Cantor Fitzgerald” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/10/10/applied-genetic-technologies-corporation-agtc-given-a-9-00-price-target-at-cantor-fitzgerald.html.

Several large investors have recently bought and sold shares of the company. Wells Fargo & Company MN grew its holdings in shares of Applied Genetic Technologies Corporation by 1.1% during the first quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 200 shares during the last quarter. Trexquant Investment LP grew its holdings in shares of Applied Genetic Technologies Corporation by 3.2% during the second quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 611 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Applied Genetic Technologies Corporation by 2.5% during the first quarter. Russell Investments Group Ltd. now owns 77,710 shares of the biotechnology company’s stock valued at $535,000 after purchasing an additional 1,883 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Applied Genetic Technologies Corporation by 13.1% during the fourth quarter. Teachers Advisors LLC now owns 22,692 shares of the biotechnology company’s stock valued at $212,000 after purchasing an additional 2,632 shares during the last quarter. Finally, Credit Suisse AG grew its holdings in shares of Applied Genetic Technologies Corporation by 10.9% during the first quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 2,662 shares during the last quarter. 54.66% of the stock is owned by institutional investors.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.